IP Library Granted Patent US 10,583,115
Granted Patent B2
US 10,583,115 · App. 15/517,755 · Granted Mar 10, 2020

Modulators of 14-3-3 functionality and uses thereof

Inventors: Joanna Woodcock (Crafers, AU); Angel Lopez (Medindie, AU); Stuart Maxwell Pitson (Glenside, AU); Michael Susithiran Samuel (North Adelaide, AU); Carl Coolen (Salisbury South, AU)
Assignees: University of South Australia; Central Adelaide Local Health Network Inc.
A61K31/395A61K9/0014A61K9/06A61K31/40A61K31/452A61K45/06A61K47/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,583,115
App. No.
15/517,755
Granted
Mar 10, 2020
Kind
B2
Abstract

The present disclosure relates to modulators of 14-3-3 functionality and their use in methods and compositions for preventing and/or treating various diseases, conditions and states, such as cancer and healing of wounds. Certain embodiments of the present disclosure provide a method of preventing and/or treating a disease, condition or state in a subject associated with altered 14-3-3 protein functionality and/or which would benefit from altering 14-3-3 functionality, the method comprising administering to the subject an effective amount of an agent which inhibits dimerization of the 14-3-3 protein, thereby preventing and/or treating the disease, condition or state in the subject.

Claims (9)

1. A method of treating a disease, condition or state in a human subject associated with increased 14-3-3 protein functionality, wherein the disease, condition or state is a lung cancer, a leukemia or a wound, the method comprising administering to the human subject an effective amount of an agent which inhibits dimerization of the 14-3-3 protein, wherein the agent comprises a compound of the following formula:

and/or

and/or a pharmaceutically acceptable salt or solvate thereof, thereby treating the disease, condition or state in the subject.

2. The method according to claim 1 , wherein the agent is administered to the subject at a concentration of 0.5-50 mg/kg body weight.

3. The method according to claim 1 , wherein the disease, condition or state is a lung cancer or a leukemia and the method further comprises administration of an anti-cancer agent.

4. The method according to claim 1 , wherein the disease, condition or state comprises a wound and the administering of the agent comprises topical administration to the wound.

5. The method according to claim 4 , wherein the subject is suffering from, or susceptible to, diabetes.

6. The method according to claim 1 , wherein the lung cancer is non-small cell lung cancer.

7. The method according to claim 1 , wherein the leukemia is T-cell leukemia.

Assignments (1)
NUNC PRO TUNC ASSIGNMENT Recorded Jun 2, 2026
From: UNIVERSITY OF SOUTH AUSTRALIA
To: ADELAIDE UNIVERSITY
Reel/Frame 075695/0898 →
Priority Claims (2)
AU 2014904015 · Oct 8, 2014 · national
AU 2014904016 · Oct 8, 2014 · national
Continuity (1)
Related Publication 20170312249A1 · Nov 2, 2017